The BRCA-P clinical trial is a breast cancer prevention trial which will enrol 2918 patients. It is open to women with a confirmed BRCA1 gene mutation who have not had a diagnosis of breast cancer. The aim of the trial is to study if using Denosumab is a safe and effective way of preventing breast cancer.
At least one in 400 women in the developed world carries the hereditary BRCA1 gene mutation. This mutation is associated with approximately 72% risk of developing breast cancer and 44% risk of developing ovarian cancer, over the course of a lifetime.
Denosumab is an antibody that switches off a molecule called RANK ligand. It is currently being used for strengthening the bones of people with osteoporosis and in people with breast and prostate cancer that has spread to the bones. Recent studies suggest switching off the RANK ligand can also inhibit the cells that cause breast cancer in women with a BRCA1 mutation.
If you are a woman between 25 and 55, with a known BRCA1 gene mutation, no current or previous breast cancer diagnosis, and not planning to have, or have not already completed surgery to remove both breasts, this trial might be suitable for you.
Participants of the trial will receive either Denosumab or a placebo drug every 6 months for 5 years.
In Queensland, you will be able to participate in the trial at the Royal Brisbane and Women's Hospital.
Read more on the Breast Cancer Trials page
Medical information disclaimer
The medical information provided is correct to the best of our knowledge, but no warranty as to accuracy is given. You must not rely on the information on our website as an alternative to medical advice from your doctor.
If you have any concerns about your health, you should seek immediate medical attention.